FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:ERBB3-EGFR (FusionGDB2 ID:27176)

Fusion Gene Summary for ERBB3-EGFR

check button Fusion gene summary
Fusion gene informationFusion gene name: ERBB3-EGFR
Fusion gene ID: 27176
HgeneTgene
Gene symbol

ERBB3

EGFR

Gene ID

2065

1956

Gene nameerb-b2 receptor tyrosine kinase 3epidermal growth factor receptor
SynonymsErbB-3|FERLK|HER3|LCCS2|MDA-BF-1|c-erbB-3|c-erbB3|erbB3-S|p180-ErbB3|p45-sErbB3|p85-sErbB3ERBB|ERBB1|HER1|NISBD2|PIG61|mENA
Cytomap

12q13.2

7p11.2

Type of geneprotein-codingprotein-coding
Descriptionreceptor tyrosine-protein kinase erbB-3human epidermal growth factor receptor 3proto-oncogene-like protein c-ErbB-3tyrosine kinase-type cell surface receptor HER3v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3epidermal growth factor receptoravian erythroblastic leukemia viral (v-erb-b) oncogene homologcell growth inhibiting protein 40cell proliferation-inducing protein 61epidermal growth factor receptor tyrosine kinase domainerb-b2 receptor tyrosine kinas
Modification date2020032720200329
UniProtAcc

P21860

P00533

Ensembl transtripts involved in fusion geneENST00000267101, ENST00000450146, 
ENST00000415288, ENST00000553131, 
ENST00000411731, ENST00000549832, 
ENST00000455089, ENST00000342916, 
ENST00000344576, ENST00000420316, 
ENST00000275493, ENST00000442591, 
ENST00000463948, ENST00000454757, 
Fusion gene scores* DoF score16 X 18 X 11=316817 X 20 X 8=2720
# samples 1922
** MAII scorelog2(19/3168*10)=-4.05950101174866
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(22/2720*10)=-3.62803122261304
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: ERBB3 [Title/Abstract] AND EGFR [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointERBB3(56492359)-EGFR(55266410), # samples:5
EGFR(55087058)-ERBB3(56492542), # samples:1
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneERBB3

GO:0007162

negative regulation of cell adhesion

7556068

HgeneERBB3

GO:0007165

signal transduction

10572067

HgeneERBB3

GO:0009968

negative regulation of signal transduction

11389077

HgeneERBB3

GO:0014065

phosphatidylinositol 3-kinase signaling

7556068

HgeneERBB3

GO:0042127

regulation of cell proliferation

11389077

HgeneERBB3

GO:0051048

negative regulation of secretion

10559227

TgeneEGFR

GO:0001934

positive regulation of protein phosphorylation

20551055

TgeneEGFR

GO:0007165

signal transduction

10572067

TgeneEGFR

GO:0007166

cell surface receptor signaling pathway

7736574

TgeneEGFR

GO:0007173

epidermal growth factor receptor signaling pathway

7736574|12435727

TgeneEGFR

GO:0008283

cell proliferation

17115032

TgeneEGFR

GO:0008284

positive regulation of cell proliferation

7736574

TgeneEGFR

GO:0010750

positive regulation of nitric oxide mediated signal transduction

12828935

TgeneEGFR

GO:0018108

peptidyl-tyrosine phosphorylation

22732145

TgeneEGFR

GO:0030307

positive regulation of cell growth

15467833

TgeneEGFR

GO:0042177

negative regulation of protein catabolic process

17115032

TgeneEGFR

GO:0042327

positive regulation of phosphorylation

15082764

TgeneEGFR

GO:0043406

positive regulation of MAP kinase activity

10572067

TgeneEGFR

GO:0045739

positive regulation of DNA repair

17115032

TgeneEGFR

GO:0045740

positive regulation of DNA replication

17115032

TgeneEGFR

GO:0045944

positive regulation of transcription by RNA polymerase II

20551055

TgeneEGFR

GO:0050679

positive regulation of epithelial cell proliferation

10572067

TgeneEGFR

GO:0050999

regulation of nitric-oxide synthase activity

12828935

TgeneEGFR

GO:0070141

response to UV-A

18483258

TgeneEGFR

GO:0070374

positive regulation of ERK1 and ERK2 cascade

20551055

TgeneEGFR

GO:0071392

cellular response to estradiol stimulus

20551055

TgeneEGFR

GO:1900020

positive regulation of protein kinase C activity

22732145

TgeneEGFR

GO:1903078

positive regulation of protein localization to plasma membrane

22732145


check buttonFusion gene breakpoints across ERBB3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across EGFR (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4ESCATCGA-Q9-A6FUERBB3chr12

56492359

+EGFRchr7

55266410

+
ChimerDB4ESCATCGA-VR-A8EYERBB3chr12

56492359

+EGFRchr7

55266410

+
ChimerDB4ESCATCGA-LN-A4A8ERBB3chr12

56492359

+EGFRchr7

55266410

+
ChimerDB4LGGTCGA-HT-8104ERBB3chr12

56492359

+EGFRchr7

55266410

+
ChimerDB4LGGTCGA-DU-7292ERBB3chr12

56492359

+EGFRchr7

55266410

+


Top

Fusion Gene ORF analysis for ERBB3-EGFR

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000267101ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000267101ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+
In-frameENST00000450146ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000450146ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+
In-frameENST00000415288ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000415288ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+
In-frameENST00000553131ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
5CDS-intronENST00000553131ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-3CDSENST00000411731ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
intron-intronENST00000411731ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-3CDSENST00000549832ENST00000455089ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000342916ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000344576ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000420316ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000275493ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000442591ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000463948ERBB3chr12

56492359

+EGFRchr7

55266410

+
5UTR-intronENST00000549832ENST00000454757ERBB3chr12

56492359

+EGFRchr7

55266410

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000267101ERBB3chr1256492359+ENST00000455089EGFRchr755266410+4153313244038411133
ENST00000450146ERBB3chr1256492359+ENST00000455089EGFRchr755266410+208810671061776556
ENST00000415288ERBB3chr1256492359+ENST00000455089EGFRchr755266410+375627358534441119
ENST00000553131ERBB3chr1256492359+ENST00000455089EGFRchr755266410+217011494821858458

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000267101ENST00000455089ERBB3chr1256492359+EGFRchr755266410+0.0017730780.99822694
ENST00000450146ENST00000455089ERBB3chr1256492359+EGFRchr755266410+0.0027948220.9972052
ENST00000415288ENST00000455089ERBB3chr1256492359+EGFRchr755266410+0.0009022220.9990978
ENST00000553131ENST00000455089ERBB3chr1256492359+EGFRchr755266410+0.0048320510.995168

Top

Fusion Genomic Features for ERBB3-EGFR


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)
ERBB3chr1256492359+EGFRchr755266409+0.0077974510.9922025
ERBB3chr1256492359+EGFRchr755266409+0.0077974510.9922025

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for ERBB3-EGFR


check button Go to

FGviewer for the breakpoints of chr12:56492359-chr7:55266410

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
ERBB3

P21860

EGFR

P00533

FUNCTION: Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908). {ECO:0000269|PubMed:15358134, ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:27416908}.FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250|UniProtKB:Q01279, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:17909029, ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:20462955, ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, ECO:0000269|PubMed:9419975}.; FUNCTION: Isoform 2 may act as an antagonist of EGF action.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269|PubMed:21516087}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228715_723897.33333333333341343.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228788_790897.33333333333341343.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228834_839897.33333333333341343.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329715_723838.33333333333341284.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329788_790838.33333333333341284.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329834_839838.33333333333341284.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+222820_643897.33333333333341343.0Topological domainExtracellular
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+232920_643838.33333333333341284.0Topological domainExtracellular
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228644_664897.33333333333341343.0TransmembraneHelical
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329644_664838.33333333333341284.0TransmembraneHelical
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016712_9790629.0DomainProtein kinase
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016712_9790706.0DomainProtein kinase
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010712_9790406.0DomainProtein kinase
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016718_7260629.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016790_7910629.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016718_7260706.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016790_7910706.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010718_7260406.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010790_7910406.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016688_7040629.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016688_7040706.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010688_7040406.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016390_6000629.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST0000034291601675_3000629.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016390_6000706.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST0000034457601675_3000706.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010390_6000406.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST0000042031601075_3000406.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST0000034291601625_6450629.0Topological domainExtracellular
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016669_12100629.0Topological domainCytoplasmic
TgeneEGFRchr12:56492359chr7:55266410ENST0000034457601625_6450706.0Topological domainExtracellular
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016669_12100706.0Topological domainCytoplasmic
TgeneEGFRchr12:56492359chr7:55266410ENST0000042031601025_6450406.0Topological domainExtracellular
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010669_12100406.0Topological domainCytoplasmic
TgeneEGFRchr12:56492359chr7:55266410ENST00000342916016646_6680629.0TransmembraneHelical
TgeneEGFRchr12:56492359chr7:55266410ENST00000344576016646_6680706.0TransmembraneHelical
TgeneEGFRchr12:56492359chr7:55266410ENST00000420316010646_6680406.0TransmembraneHelical

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228709_966897.33333333333341343.0DomainProtein kinase
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13709_9660184.0DomainProtein kinase
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329709_966838.33333333333341284.0DomainProtein kinase
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915709_966254.33333333333334700.0DomainProtein kinase
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13715_7230184.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13788_7900184.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13834_8390184.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915715_723254.33333333333334700.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915788_790254.33333333333334700.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915834_839254.33333333333334700.0Nucleotide bindingNote=ATP
HgeneERBB3chr12:56492359chr7:55266410ENST00000267101+2228665_1342897.33333333333341343.0Topological domainCytoplasmic
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+1320_6430184.0Topological domainExtracellular
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13665_13420184.0Topological domainCytoplasmic
HgeneERBB3chr12:56492359chr7:55266410ENST00000415288+2329665_1342838.33333333333341284.0Topological domainCytoplasmic
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+91520_643254.33333333333334700.0Topological domainExtracellular
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915665_1342254.33333333333334700.0Topological domainCytoplasmic
HgeneERBB3chr12:56492359chr7:55266410ENST00000411731+13644_6640184.0TransmembraneHelical
HgeneERBB3chr12:56492359chr7:55266410ENST00000450146+915644_664254.33333333333334700.0TransmembraneHelical
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128712_979900.33333333333341211.0DomainProtein kinase
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128718_726900.33333333333341211.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128790_791900.33333333333341211.0Nucleotide bindingATP
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128688_704900.33333333333341211.0RegionNote=Important for dimerization%2C phosphorylation and activation
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128390_600900.33333333333341211.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST00000275493212875_300900.33333333333341211.0RepeatNote=Approximate
TgeneEGFRchr12:56492359chr7:55266410ENST00000275493212825_645900.33333333333341211.0Topological domainExtracellular
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128669_1210900.33333333333341211.0Topological domainCytoplasmic
TgeneEGFRchr12:56492359chr7:55266410ENST000002754932128646_668900.33333333333341211.0TransmembraneHelical


Top

Fusion Gene Sequence for ERBB3-EGFR


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000267101_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(transcript)=4153nt_BP=3132nt
ATTACCCTTCCCTGGATCTGGGGGCTTTCGGAATCTCGACCTCCCCTTGGCCTATCTCCTGCAGAAAAATTAGGGTGAGCCCCATCCTCG
ATCTGCTCCGCCAAGTTGCGGGACCGCGGGGCGTGGCACGCTCGGGGCAGGCGGTCCGAGGCTCCGCAATCCCTACTCCAGCCTCGCGCG
GGAGGGGGCGCGGCCGTGACTCACCCCCTTCCCTCTGCGTTCCTCCCTCCCTCTCTCTCTCTCTCTCACACACACACACCCCTCCCCTGC
CATCCCTCCCCGGACTCCGGCTCCGGCTCCGATTGCAATTTGCAACCTCCGCTGCCGTCGCCGCAGCAGCCACCAATTCGCCAGCGGTTC
AGGTGGCTCTTGCCTCGATGTCCTAGCCTAGGGGCCCCCGGGCCGGACTTGGCTGGGCTCCCTTCACCCTCTGCGGAGTCATGAGGGCGA
ACGACGCTCTGCAGGTGCTGGGCTTGCTTTTCAGCCTGGCCCGGGGCTCCGAGGTGGGCAACTCTCAGGCAGTGTGTCCTGGGACTCTGA
ATGGCCTGAGTGTGACCGGCGATGCTGAGAACCAATACCAGACACTGTACAAGCTCTACGAGAGGTGTGAGGTGGTGATGGGGAACCTTG
AGATTGTGCTCACGGGACACAATGCCGACCTCTCCTTCCTGCAGTGGATTCGAGAAGTGACAGGCTATGTCCTCGTGGCCATGAATGAAT
TCTCTACTCTACCATTGCCCAACCTCCGCGTGGTGCGAGGGACCCAGGTCTACGATGGGAAGTTTGCCATCTTCGTCATGTTGAACTATA
ACACCAACTCCAGCCACGCTCTGCGCCAGCTCCGCTTGACTCAGCTCACCGAGATTCTGTCAGGGGGTGTTTATATTGAGAAGAACGATA
AGCTTTGTCACATGGACACAATTGACTGGAGGGACATCGTGAGGGACCGAGATGCTGAGATAGTGGTGAAGGACAATGGCAGAAGCTGTC
CCCCCTGTCATGAGGTTTGCAAGGGGCGATGCTGGGGTCCTGGATCAGAAGACTGCCAGACATTGACCAAGACCATCTGTGCTCCTCAGT
GTAATGGTCACTGCTTTGGGCCCAACCCCAACCAGTGCTGCCATGATGAGTGTGCCGGGGGCTGCTCAGGCCCTCAGGACACAGACTGCT
TTGCCTGCCGGCACTTCAATGACAGTGGAGCCTGTGTACCTCGCTGTCCACAGCCTCTTGTCTACAACAAGCTAACTTTCCAGCTGGAAC
CCAATCCCCACACCAAGTATCAGTATGGAGGAGTTTGTGTAGCCAGCTGTCCCCATAACTTTGTGGTGGATCAAACATCCTGTGTCAGGG
CCTGTCCTCCTGACAAGATGGAAGTAGATAAAAATGGGCTCAAGATGTGTGAGCCTTGTGGGGGACTATGTCCCAAAGCCTGTGAGGGAA
CAGGCTCTGGGAGCCGCTTCCAGACTGTGGACTCGAGCAACATTGATGGATTTGTGAACTGCACCAAGATCCTGGGCAACCTGGACTTTC
TGATCACCGGCCTCAATGGAGACCCCTGGCACAAGATCCCTGCCCTGGACCCAGAGAAGCTCAATGTCTTCCGGACAGTACGGGAGATCA
CAGGTTACCTGAACATCCAGTCCTGGCCGCCCCACATGCACAACTTCAGTGTTTTTTCCAATTTGACAACCATTGGAGGCAGAAGCCTCT
ACAACCGGGGCTTCTCATTGTTGATCATGAAGAACTTGAATGTCACATCTCTGGGCTTCCGATCCCTGAAGGAAATTAGTGCTGGGCGTA
TCTATATAAGTGCCAATAGGCAGCTCTGCTACCACCACTCTTTGAACTGGACCAAGGTGCTTCGGGGGCCTACGGAAGAGCGACTAGACA
TCAAGCATAATCGGCCGCGCAGAGACTGCGTGGCAGAGGGCAAAGTGTGTGACCCACTGTGCTCCTCTGGGGGATGCTGGGGCCCAGGCC
CTGGTCAGTGCTTGTCCTGTCGAAATTATAGCCGAGGAGGTGTCTGTGTGACCCACTGCAACTTTCTGAATGGGGAGCCTCGAGAATTTG
CCCATGAGGCCGAATGCTTCTCCTGCCACCCGGAATGCCAACCCATGGAGGGCACTGCCACATGCAATGGCTCGGGCTCTGATACTTGTG
CTCAATGTGCCCATTTTCGAGATGGGCCCCACTGTGTGAGCAGCTGCCCCCATGGAGTCCTAGGTGCCAAGGGCCCAATCTACAAGTACC
CAGATGTTCAGAATGAATGTCGGCCCTGCCATGAGAACTGCACCCAGGGGTGTAAAGGACCAGAGCTTCAAGACTGTTTAGGACAAACAC
TGGTGCTGATCGGCAAAACCCATCTGACAATGGCTTTGACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGGGCGGCACTTTTC
TCTACTGGCGTGGGCGCCGGATTCAGAATAAAAGGGCTATGAGGCGATACTTGGAACGGGGTGAGAGCATAGAGCCTCTGGACCCCAGTG
AGAAGGCTAACAAAGTCTTGGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGGTGTCTTTGGAACTGTGC
ACAAAGGAGTGTGGATCCCTGAGGGTGAATCAATCAAGATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGGCAGAGTTTTC
AAGCTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATGCCCACATTGTAAGGCTGCTGGGACTATGCCCAGGGTCATCTCTGC
AGCTTGTCACTCAATATTTGCCTCTGGGTTCTCTGCTGGATCATGTGAGACAACACCGGGGGGCACTGGGGCCACAGCTGCTGCTCAACT
GGGGAGTACAAATTGCCAAGGGAATGTACTACCTTGAGGAACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACTCAAGT
CACCCAGTCAGGTTCAGGTGGCAGATTTTGGTGTGGCTGACCTGCTGCCTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAAGACTC
CAATTAAGTGGATGGCCCTTGAGAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAGCTATGGGGTGACTGTTTGGGAGT
TGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCAC
CCATATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAGTTCCGTGAGTTGATCATCG
AATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTCATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACT
TCTACCGTGCCCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAGCAGCC
CCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAA
GCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCC
TCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAA
GCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGA
CCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCA
AATCACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAG
ATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAACGTATATTTAACTAATTAAATATTAGTTAATATTAATAAATTTTA

>In-frame_ENST00000267101_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(amino acids)=1133AA_start in transcript=440_stop in transcript=3841
MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVA
MNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNG
RSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTF
QLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGN
LDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEIS
AGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEP
REFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCL
GQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVF
GTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQL
LLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVT
VWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPT
DSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSID

--------------------------------------------------------------
>In-frame_ENST00000450146_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(transcript)=2088nt_BP=1067nt
AATTTGCAACCTCCGCTGCCGTCGCCGCAGCAGCCACCAATTCGCCAGCGGTTCAGGTGGCTCTTGCCTCGATGTCCTAGCCTAGGGGCC
CCCGGGCCGGACTTGGCTGGGCTCCCTTCACCCTCTGCGGAGTCATGAGGGCGAACGACGCTCTGCAGGTGCCAAGGGCCCAATCTACAA
GTACCCAGATGTTCAGAATGAATGTCGGCCCTGCCATGAGAACTGCACCCAGGGGTGTAAAGGACCAGAGCTTCAAGACTGTTTAGGACA
AACACTGGTGCTGATCGGCAAAACCCATCTGACAATGGCTTTGACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGGGCGGCAC
TTTTCTCTACTGGCGTGGGCGCCGGATTCAGAATAAAAGGGCTATGAGGCGATACTTGGAACGGGGTGAGAGCATAGAGCCTCTGGACCC
CAGTGAGAAGGCTAACAAAGTCTTGGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGGTGTCTTTGGAAC
TGTGCACAAAGGAGTGTGGATCCCTGAGGGTGAATCAATCAAGATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGGCAGAG
TTTTCAAGCTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATGCCCACATTGTAAGGCTGCTGGGACTATGCCCAGGGTCATC
TCTGCAGCTTGTCACTCAATATTTGCCTCTGGGTTCTCTGCTGGATCATGTGAGACAACACCGGGGGGCACTGGGGCCACAGCTGCTGCT
CAACTGGGGAGTACAAATTGCCAAGGGAATGTACTACCTTGAGGAACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACT
CAAGTCACCCAGTCAGGTTCAGGTGGCAGATTTTGGTGTGGCTGACCTGCTGCCTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAA
GACTCCAATTAAGTGGATGGCCCTTGAGAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAGCTATGGGGTGACTGTTTG
GGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCA
GCCACCCATATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAGTTCCGTGAGTTGAT
CATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTCATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTC
CAACTTCTACCGTGCCCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAG
CAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCT
GCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACAC
CTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTG
TCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACA
CATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATG
AAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGT
GACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAACGTATATTTAACTAATTAAATATTAGTTAATATTAATAAA

>In-frame_ENST00000450146_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(amino acids)=556AA_start in transcript=106_stop in transcript=1776
MGSLHPLRSHEGERRSAGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTMALTVIAGLVVIFMMLGGTFLYWR
GRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVT
DHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQ
VQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICT
IDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTS
RTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPGEWLVWKQSCSSTSSTHSAAASLQCPSQVL

--------------------------------------------------------------
>In-frame_ENST00000415288_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(transcript)=3756nt_BP=2735nt
ATTTATTCCAGGACCTAGAGAGAGGCAGGATGAGGGTAGAGAATTAACCCCTTAGTACCCAAAAGAAGCACAGAGGGGTCCCAGGTTGAA
AAAGGAAATCTTTTCACCTTCCCATTCATGGAATGTGTGTCCTGGGACTCTGAATGGCCTGAGTGTGACCGGCGATGCTGAGAACCAATA
CCAGACACTGTACAAGCTCTACGAGAGGTGTGAGGTGGTGATGGGGAACCTTGAGATTGTGCTCACGGGACACAATGCCGACCTCTCCTT
CCTGCAGTGGATTCGAGAAGTGACAGGCTATGTCCTCGTGGCCATGAATGAATTCTCTACTCTACCATTGCCCAACCTCCGCGTGGTGCG
AGGGACCCAGGTCTACGATGGGAAGTTTGCCATCTTCGTCATGTTGAACTATAACACCAACTCCAGCCACGCTCTGCGCCAGCTCCGCTT
GACTCAGCTCACCGAGATTCTGTCAGGGGGTGTTTATATTGAGAAGAACGATAAGCTTTGTCACATGGACACAATTGACTGGAGGGACAT
CGTGAGGGACCGAGATGCTGAGATAGTGGTGAAGGACAATGGCAGAAGCTGTCCCCCCTGTCATGAGGTTTGCAAGGGGCGATGCTGGGG
TCCTGGATCAGAAGACTGCCAGACATTGACCAAGACCATCTGTGCTCCTCAGTGTAATGGTCACTGCTTTGGGCCCAACCCCAACCAGTG
CTGCCATGATGAGTGTGCCGGGGGCTGCTCAGGCCCTCAGGACACAGACTGCTTTGCCTGCCGGCACTTCAATGACAGTGGAGCCTGTGT
ACCTCGCTGTCCACAGCCTCTTGTCTACAACAAGCTAACTTTCCAGCTGGAACCCAATCCCCACACCAAGTATCAGTATGGAGGAGTTTG
TGTAGCCAGCTGTCCCCATAACTTTGTGGTGGATCAAACATCCTGTGTCAGGGCCTGTCCTCCTGACAAGATGGAAGTAGATAAAAATGG
GCTCAAGATGTGTGAGCCTTGTGGGGGACTATGTCCCAAAGCCTGTGAGGGAACAGGCTCTGGGAGCCGCTTCCAGACTGTGGACTCGAG
CAACATTGATGGATTTGTGAACTGCACCAAGATCCTGGGCAACCTGGACTTTCTGATCACCGGCCTCAATGGAGACCCCTGGCACAAGAT
CCCTGCCCTGGACCCAGAGAAGCTCAATGTCTTCCGGACAGTACGGGAGATCACAGGTTACCTGAACATCCAGTCCTGGCCGCCCCACAT
GCACAACTTCAGTGTTTTTTCCAATTTGACAACCATTGGAGGCAGAAGCCTCTACAACCGGGGCTTCTCATTGTTGATCATGAAGAACTT
GAATGTCACATCTCTGGGCTTCCGATCCCTGAAGGAAATTAGTGCTGGGCGTATCTATATAAGTGCCAATAGGCAGCTCTGCTACCACCA
CTCTTTGAACTGGACCAAGGTGCTTCGGGGGCCTACGGAAGAGCGACTAGACATCAAGCATAATCGGCCGCGCAGAGACTGCGTGGCAGA
GGGCAAAGTGTGTGACCCACTGTGCTCCTCTGGGGGATGCTGGGGCCCAGGCCCTGGTCAGTGCTTGTCCTGTCGAAATTATAGCCGAGG
AGGTGTCTGTGTGACCCACTGCAACTTTCTGAATGGGGAGCCTCGAGAATTTGCCCATGAGGCCGAATGCTTCTCCTGCCACCCGGAATG
CCAACCCATGGAGGGCACTGCCACATGCAATGGCTCGGGCTCTGATACTTGTGCTCAATGTGCCCATTTTCGAGATGGGCCCCACTGTGT
GAGCAGCTGCCCCCATGGAGTCCTAGGTGCCAAGGGCCCAATCTACAAGTACCCAGATGTTCAGAATGAATGTCGGCCCTGCCATGAGAA
CTGCACCCAGGGGTGTAAAGGACCAGAGCTTCAAGACTGTTTAGGACAAACACTGGTGCTGATCGGCAAAACCCATCTGACAATGGCTTT
GACAGTGATAGCAGGATTGGTAGTGATTTTCATGATGCTGGGCGGCACTTTTCTCTACTGGCGTGGGCGCCGGATTCAGAATAAAAGGGC
TATGAGGCGATACTTGGAACGGGGTGAGAGCATAGAGCCTCTGGACCCCAGTGAGAAGGCTAACAAAGTCTTGGCCAGAATCTTCAAAGA
GACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGGTGTCTTTGGAACTGTGCACAAAGGAGTGTGGATCCCTGAGGGTGAATCAATCAA
GATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGGCAGAGTTTTCAAGCTGTGACAGATCATATGCTGGCCATTGGCAGCCT
GGACCATGCCCACATTGTAAGGCTGCTGGGACTATGCCCAGGGTCATCTCTGCAGCTTGTCACTCAATATTTGCCTCTGGGTTCTCTGCT
GGATCATGTGAGACAACACCGGGGGGCACTGGGGCCACAGCTGCTGCTCAACTGGGGAGTACAAATTGCCAAGGGAATGTACTACCTTGA
GGAACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACTCAAGTCACCCAGTCAGGTTCAGGTGGCAGATTTTGGTGTGGC
TGACCTGCTGCCTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAAGACTCCAATTAAGTGGATGGCCCTTGAGAGTATCCACTTTGG
GAAATACACACACCAGAGTGATGTCTGGAGCTATGGGGTGACTGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCC
TGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACCATCGATGTCTACATGATCATGGTCAA
GTGCTGGATGATAGACGCAGATAGTCGCCCAAAGTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCT
TGTCATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCCCTGATGGATGAAGAAGACATGGACGA
CGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAG
TGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATCAAGGAAGACAGCTTCTTGCAGCGATA
CAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTC
CTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCCAGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAAC
AGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCGAGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTT
TGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAATCACGGACATACACATCTGTGTGTGTGAGTGTTCA
TGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATTTGATCCCTGTTCTCTCTGCTGGCTCTATCTTGAC

>In-frame_ENST00000415288_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(amino acids)=1119AA_start in transcript=85_stop in transcript=3444
MKKEIFSPSHSWNVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRV
VRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRC
WGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGG
VCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWH
KIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCY
HHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHP
ECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTM
ALTVIAGLVVIFMMLGGTFLYWRGRRIQNKRAMRRYLERGESIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGES
IKIPVCIKVIEDKSGRQSFQAVTDHMLAIGSLDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYY
LEEHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGSKPYDG
IPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDM
DDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPGEWLVWK

--------------------------------------------------------------
>In-frame_ENST00000553131_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(transcript)=2170nt_BP=1149nt
AGAACACTGGTCAGAGAAATGGGAGGCATGCATTCTAGTCCTGATTTTGCCATTAATTTGCCACATGACTTTGAAGAAGTTACTTATCTT
CTCTGTGCCTCGGTTTATGCATCTATACAGAGGAAATAACATTTGTCCTTCCAGGATGGCTGTAAGGGTAAAGGGGGATGATGTATGTGA
AAGTGCTTTGGAAAGCACAGAGCACTGTATAAAAGGTACTCAAGGTGGTAATAGTACTACCAACTCTCCCTAGCTGTCCCCTTCCCCACT
TTGTGCTCCTCCATCAAAGGGAAAACCCAACCCCTTTGATTCCTGATCTCATGAGCACAAATAACTTCCTCAGTTCTCAGGGTCTGTACC
TCAATATGCCTATAATCCATTCCAGGACTAACGGTGCTTCCTCTTCCTGCCCTTTCAGCTGTGCTGCTTTTGGCATTCACCTATGAGGAG
CGGGTTGGAGTGGGACATGGGAATGGCCTTTCCTGAGTAACTCCTTCCCATTTGCTCCTCAGAGCATAGAGCCTCTGGACCCCAGTGAGA
AGGCTAACAAAGTCTTGGCCAGAATCTTCAAAGAGACAGAGCTAAGGAAGCTTAAAGTGCTTGGCTCGGGTGTCTTTGGAACTGTGCACA
AAGGAGTGTGGATCCCTGAGGGTGAATCAATCAAGATTCCAGTCTGCATTAAAGTCATTGAGGACAAGAGTGGACGGCAGAGTTTTCAAG
CTGTGACAGATCATATGCTGGCCATTGGCAGCCTGGACCATGCCCACATTGTAAGGCTGCTGGGACTATGCCCAGGGTCATCTCTGCAGC
TTGTCACTCAATATTTGCCTCTGGGTTCTCTGCTGGATCATGTGAGACAACACCGGGGGGCACTGGGGCCACAGCTGCTGCTCAACTGGG
GAGTACAAATTGCCAAGGGAATGTACTACCTTGAGGAACATGGTATGGTGCATAGAAACCTGGCTGCCCGAAACGTGCTACTCAAGTCAC
CCAGTCAGGTTCAGGTGGCAGATTTTGGTGTGGCTGACCTGCTGCCTCCTGATGATAAGCAGCTGCTATACAGTGAGGCCAAGACTCCAA
TTAAGTGGATGGCCCTTGAGAGTATCCACTTTGGGAAATACACACACCAGAGTGATGTCTGGAGCTATGGGGTGACTGTTTGGGAGTTGA
TGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCCAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCA
TATGTACCATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAGTTCCGTGAGTTGATCATCGAAT
TCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTCATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCT
ACCGTGCCCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAGCAGGGCTTCTTCAGCAGCCCCT
CCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCAACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCT
GTCCCATCAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCC
CAGTGCCTGGTGAGTGGCTTGTCTGGAAACAGTCCTGCTCCTCAACCTCCTCGACCCACTCAGCAGCAGCCAGTCTCCAGTGTCCAAGCC
AGGTGCTCCCTCCAGCATCTCCAGAGGGGGAAACAGTGGCAGATTTGCAGACACAGTGAAGGGCGTAAGGAGCAGATAAACACATGACCG
AGCCTGCACAAGCTCTTTGTTGTGTCTGGTTGTTTGCTGTACCTCTGTTGTAAGAATGAATCTGCAAAATTTCTAGCTTATGAAGCAAAT
CACGGACATACACATCTGTGTGTGTGAGTGTTCATGATGTGTGTACATCTGTGTATGTGTGTGTGTGTATGTGTGTGTTTGTGACAGATT
TGATCCCTGTTCTCTCTGCTGGCTCTATCTTGACCTGTGAAACGTATATTTAACTAATTAAATATTAGTTAATATTAATAAATTTTAAGC

>In-frame_ENST00000553131_ENST00000455089_TCGA-Q9-A6FU_ERBB3_chr12_56492359_+_EGFR_chr7_55266410_length(amino acids)=458AA_start in transcript=482_stop in transcript=1858
MSNSFPFAPQSIEPLDPSEKANKVLARIFKETELRKLKVLGSGVFGTVHKGVWIPEGESIKIPVCIKVIEDKSGRQSFQAVTDHMLAIGS
LDHAHIVRLLGLCPGSSLQLVTQYLPLGSLLDHVRQHRGALGPQLLLNWGVQIAKGMYYLEEHGMVHRNLAARNVLLKSPSQVQVADFGV
ADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMV
KCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSL
SATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPGEWLVWKQSCSSTSSTHSAAASLQCPSQVLPPASPEGE

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for ERBB3-EGFR


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for ERBB3-EGFR


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgeneERBB3P21860DB11652TucatinibInhibitorSmall moleculeApproved|Investigational
HgeneERBB3P21860DB11652TucatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB00002CetuximabAntagonistBiotechApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB05294VandetanibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB08916AfatinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB09330OsimertinibInhibitorSmall moleculeApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00317GefitinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00530ErlotinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01259LapatinibAntagonistSmall moleculeApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB01269PanitumumabSuppressorBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB09559NecitumumabAntagonistBiotechApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11828NeratinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB11963DacomitinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB15035ZanubrutinibInhibitorSmall moleculeApproved|Investigational
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved
TgeneEGFRP00533DB00281LidocaineAntagonistSmall moleculeApproved|Vet_approved

Top

Related Diseases for ERBB3-EGFR


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneERBB3C0036341Schizophrenia3PSYGENET
HgeneERBB3C1843478Lethal Congenital Contracture Syndrome 23CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneERBB3C0006142Malignant neoplasm of breast2CTD_human
HgeneERBB3C0678222Breast Carcinoma2CTD_human
HgeneERBB3C1257931Mammary Neoplasms, Human2CTD_human
HgeneERBB3C1458155Mammary Neoplasms2CTD_human
HgeneERBB3C4704874Mammary Carcinoma, Human2CTD_human
HgeneERBB3C0005586Bipolar Disorder1PSYGENET
HgeneERBB3C0011570Mental Depression1PSYGENET
HgeneERBB3C0016978gallbladder neoplasm1CTD_human
HgeneERBB3C0024121Lung Neoplasms1CTD_human
HgeneERBB3C0027627Neoplasm Metastasis1CTD_human
HgeneERBB3C0033578Prostatic Neoplasms1CTD_human
HgeneERBB3C0041696Unipolar Depression1PSYGENET
HgeneERBB3C0153452Malignant neoplasm of gallbladder1CTD_human
HgeneERBB3C0235874Disease Exacerbation1CTD_human
HgeneERBB3C0242379Malignant neoplasm of lung1CTD_human
HgeneERBB3C0376358Malignant neoplasm of prostate1CTD_human
HgeneERBB3C1269683Major Depressive Disorder1PSYGENET
HgeneERBB3C2931822Nasopharyngeal carcinoma1CTD_human
HgeneERBB3C4746575ERYTHROLEUKEMIA, FAMILIAL, SUSCEPTIBILITY TO1UNIPROT
TgeneEGFRC0007131Non-Small Cell Lung Carcinoma16CGI;CTD_human
TgeneEGFRC0024121Lung Neoplasms7CGI;CTD_human
TgeneEGFRC0242379Malignant neoplasm of lung7CGI;CTD_human
TgeneEGFRC0006142Malignant neoplasm of breast6CTD_human
TgeneEGFRC0678222Breast Carcinoma6CTD_human
TgeneEGFRC1257931Mammary Neoplasms, Human6CTD_human
TgeneEGFRC1458155Mammary Neoplasms6CTD_human
TgeneEGFRC4704874Mammary Carcinoma, Human6CTD_human
TgeneEGFRC0001418Adenocarcinoma5CTD_human
TgeneEGFRC0205641Adenocarcinoma, Basal Cell5CTD_human
TgeneEGFRC0205642Adenocarcinoma, Oxyphilic5CTD_human
TgeneEGFRC0205643Carcinoma, Cribriform5CTD_human
TgeneEGFRC0205644Carcinoma, Granular Cell5CTD_human
TgeneEGFRC0205645Adenocarcinoma, Tubular5CTD_human
TgeneEGFRC0334588Giant Cell Glioblastoma5CTD_human;ORPHANET
TgeneEGFRC0007137Squamous cell carcinoma3CTD_human
TgeneEGFRC0007873Uterine Cervical Neoplasm3CTD_human
TgeneEGFRC0014859Esophageal Neoplasms3CGI;CTD_human
TgeneEGFRC0017636Glioblastoma3CGI;CTD_human
TgeneEGFRC0018671Head and Neck Neoplasms3CGI;CTD_human
TgeneEGFRC0018675Head Neoplasms3CTD_human
TgeneEGFRC0024623Malignant neoplasm of stomach3CTD_human
TgeneEGFRC0027533Neck Neoplasms3CTD_human
TgeneEGFRC0027627Neoplasm Metastasis3CTD_human
TgeneEGFRC0033578Prostatic Neoplasms3CTD_human
TgeneEGFRC0038356Stomach Neoplasms3CTD_human
TgeneEGFRC0278996Malignant Head and Neck Neoplasm3CGI;CTD_human
TgeneEGFRC0376358Malignant neoplasm of prostate3CTD_human
TgeneEGFRC0546837Malignant neoplasm of esophagus3CGI;CTD_human
TgeneEGFRC0746787Cancer of Neck3CTD_human
TgeneEGFRC0751177Cancer of Head3CTD_human
TgeneEGFRC0887900Upper Aerodigestive Tract Neoplasms3CTD_human
TgeneEGFRC1621958Glioblastoma Multiforme3CTD_human
TgeneEGFRC1708349Hereditary Diffuse Gastric Cancer3CTD_human
TgeneEGFRC4048328cervical cancer3CTD_human
TgeneEGFRC0005684Malignant neoplasm of urinary bladder2CTD_human
TgeneEGFRC0005695Bladder Neoplasm2CTD_human
TgeneEGFRC0007102Malignant tumor of colon2CTD_human
TgeneEGFRC0009375Colonic Neoplasms2CTD_human
TgeneEGFRC0009402Colorectal Carcinoma2CTD_human
TgeneEGFRC0009404Colorectal Neoplasms2CTD_human
TgeneEGFRC0024668Mammary Neoplasms, Experimental2CTD_human
TgeneEGFRC0027626Neoplasm Invasiveness2CTD_human
TgeneEGFRC0027643Neoplasm Recurrence, Local2CTD_human
TgeneEGFRC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
TgeneEGFRC0206726gliosarcoma2ORPHANET
TgeneEGFRC0919267ovarian neoplasm2CTD_human
TgeneEGFRC1140680Malignant neoplasm of ovary2CTD_human
TgeneEGFRC4015130INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 22CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneEGFRC0001973Alcoholic Intoxication, Chronic1PSYGENET
TgeneEGFRC0003865Arthritis, Adjuvant-Induced1CTD_human
TgeneEGFRC0005396Bile Duct Neoplasms1CTD_human
TgeneEGFRC0007097Carcinoma1CTD_human
TgeneEGFRC0007113Rectal Carcinoma1CTD_human
TgeneEGFRC0007193Cardiomyopathy, Dilated1CTD_human
TgeneEGFRC0011603Dermatitis1CTD_human
TgeneEGFRC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
TgeneEGFRC0014175Endometriosis1CTD_human
TgeneEGFRC0016978gallbladder neoplasm1CTD_human
TgeneEGFRC0021655Insulin Resistance1CTD_human
TgeneEGFRC0022660Kidney Failure, Acute1CTD_human
TgeneEGFRC0024667Animal Mammary Neoplasms1CTD_human
TgeneEGFRC0024809Marijuana Abuse1PSYGENET
TgeneEGFRC0025500Mesothelioma1CTD_human
TgeneEGFRC0027439Nasopharyngeal Neoplasms1CTD_human
TgeneEGFRC0029463Osteosarcoma1CTD_human
TgeneEGFRC0030297Pancreatic Neoplasm1CTD_human
TgeneEGFRC0030354Papilloma1CTD_human
TgeneEGFRC0032580Adenomatous Polyposis Coli1CTD_human
TgeneEGFRC0034885Rectal Neoplasms1CTD_human
TgeneEGFRC0041696Unipolar Depression1PSYGENET
TgeneEGFRC0085548Autosomal Recessive Polycystic Kidney Disease1CTD_human
TgeneEGFRC0085762Alcohol abuse1PSYGENET
TgeneEGFRC0149925Small cell carcinoma of lung1CTD_human
TgeneEGFRC0153452Malignant neoplasm of gallbladder1CTD_human
TgeneEGFRC0205696Anaplastic carcinoma1CTD_human
TgeneEGFRC0205697Carcinoma, Spindle-Cell1CTD_human
TgeneEGFRC0205698Undifferentiated carcinoma1CTD_human
TgeneEGFRC0205699Carcinomatosis1CTD_human
TgeneEGFRC0205874Papilloma, Squamous Cell1CTD_human
TgeneEGFRC0205875Papillomatosis1CTD_human
TgeneEGFRC0206686Adrenocortical carcinoma1CTD_human
TgeneEGFRC0206698Cholangiocarcinoma1CTD_human
TgeneEGFRC0235874Disease Exacerbation1CTD_human
TgeneEGFRC0238301Cancer of Nasopharynx1CTD_human
TgeneEGFRC0263454Chloracne1CTD_human
TgeneEGFRC0269102Endometrioma1CTD_human
TgeneEGFRC0279626Squamous cell carcinoma of esophagus1CGI;CTD_human
TgeneEGFRC0345905Intrahepatic Cholangiocarcinoma1CTD_human
TgeneEGFRC0345967Malignant mesothelioma1CTD_human
TgeneEGFRC0346647Malignant neoplasm of pancreas1CTD_human
TgeneEGFRC0376634Craniofacial Abnormalities1CTD_human
TgeneEGFRC0740277Bile duct carcinoma1CTD_human
TgeneEGFRC0920563Insulin Sensitivity1CTD_human
TgeneEGFRC0971858Arthritis, Collagen-Induced1CTD_human
TgeneEGFRC0993582Arthritis, Experimental1CTD_human
TgeneEGFRC1257925Mammary Carcinoma, Animal1CTD_human
TgeneEGFRC1269683Major Depressive Disorder1PSYGENET
TgeneEGFRC1449563Cardiomyopathy, Familial Idiopathic1CTD_human
TgeneEGFRC1565662Acute Kidney Insufficiency1CTD_human
TgeneEGFRC2239176Liver carcinoma1CTD_human
TgeneEGFRC2609414Acute kidney injury1CTD_human
TgeneEGFRC2713442Polyposis, Adenomatous Intestinal1CTD_human
TgeneEGFRC2713443Familial Intestinal Polyposis1CTD_human
TgeneEGFRC3805278Extrahepatic Cholangiocarcinoma1CTD_human
TgeneEGFRC4751120Neonatal inflammatory skin and bowel disease1ORPHANET